Merck is undergoing a strategic restructuring, resulting in immediate job cuts in administration, sales, and research as part of a plan to save $3 billion by 2027.

Merck’s stock is falling after a rare revenue miss, and the announcement of a $3 billion cost-cutting plan that will include layoffs.

Merck on Wednesday agreed to buy privately held biotech EyeBio for as much as $3 billion, as it looks to diversify its portfolio of experimental drugs with treatments for eye diseases.

Top Stories Pentagon ending contracts Winning $389K win vanishes Delta passengers stranded La Niña is dead Diet and lung cancer risk ChatGPT AI action figure trend ...

Posted 2024-01-22T19:47:52Z - Updated 2024-01-22T20:50:07Z By David Arkin This article was written for our sponsor, North Carolina Biotechnology Center ...

Raleigh’s Verona Pharma acquired by Merck for $10 billion as maker of COPD treatment Ohtuvayre merges with pharmaceutical company with growing Durham, NC footprint ...

Merck has been in north Durham since 2004. Last year, its Bull City campus produced 70.7 million doses, a figure the company expects to rise. “That number will continue to increase as we receive ...

Merck to acquire Verona Pharma for $10B, gaining Ohtuvayre, a breakthrough COPD treatment with rapid uptake since its 2024 launch.

Merck MRK 3.56% is making a big bet that its new drug, approved Tuesday in the U.S. for a potentially fatal lung disease, will take the company a long way toward heading off a massive revenue ...

Merck to Buy Verona Pharma in $10 Billion Deal Deal is a 23% premium to Tuesday’s closing price for the London-based company By Colin Kellaher Share ...

DURHAM -- Merck & Co. Inc. said yesterday that it plans to spend about $300 million on a second expansion of its vaccine-manufacturing plant in Durham. The expansion will include up to 180 new jobs.

DURHAM – North Carolina’s unemployment rate is still hovering near 10 percent, but don’t tell that to pharmaceutical giant Merck & Co. By the end of this year, Merck will grow its Durham ...